1. Home
  2. VIRX vs GURE Comparison

VIRX vs GURE Comparison

Compare VIRX & GURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIRX
  • GURE
  • Stock Information
  • Founded
  • VIRX 2007
  • GURE 2006
  • Country
  • VIRX United States
  • GURE China
  • Employees
  • VIRX N/A
  • GURE N/A
  • Industry
  • VIRX Biotechnology: Pharmaceutical Preparations
  • GURE Major Chemicals
  • Sector
  • VIRX Health Care
  • GURE Industrials
  • Exchange
  • VIRX Nasdaq
  • GURE Nasdaq
  • Market Cap
  • VIRX 7.0M
  • GURE 5.7M
  • IPO Year
  • VIRX N/A
  • GURE 1992
  • Fundamental
  • Price
  • VIRX $0.19
  • GURE $0.72
  • Analyst Decision
  • VIRX Buy
  • GURE
  • Analyst Count
  • VIRX 4
  • GURE 0
  • Target Price
  • VIRX $5.00
  • GURE N/A
  • AVG Volume (30 Days)
  • VIRX 2.3M
  • GURE 233.7K
  • Earning Date
  • VIRX 11-13-2024
  • GURE 11-19-2024
  • Dividend Yield
  • VIRX N/A
  • GURE N/A
  • EPS Growth
  • VIRX N/A
  • GURE N/A
  • EPS
  • VIRX N/A
  • GURE N/A
  • Revenue
  • VIRX N/A
  • GURE $12,802,982.00
  • Revenue This Year
  • VIRX N/A
  • GURE N/A
  • Revenue Next Year
  • VIRX N/A
  • GURE N/A
  • P/E Ratio
  • VIRX N/A
  • GURE N/A
  • Revenue Growth
  • VIRX N/A
  • GURE N/A
  • 52 Week Low
  • VIRX $0.13
  • GURE $0.50
  • 52 Week High
  • VIRX $1.31
  • GURE $1.79
  • Technical
  • Relative Strength Index (RSI)
  • VIRX 48.39
  • GURE 55.92
  • Support Level
  • VIRX $0.20
  • GURE $0.50
  • Resistance Level
  • VIRX $0.24
  • GURE $0.64
  • Average True Range (ATR)
  • VIRX 0.03
  • GURE 0.13
  • MACD
  • VIRX -0.00
  • GURE 0.02
  • Stochastic Oscillator
  • VIRX 34.27
  • GURE 22.35

About VIRX Viracta Therapeutics Inc.

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

About GURE Gulf Resources Inc. (NV)

Gulf Resources Inc is a holding company engaged in the manufacture and trade of bromine and crude salt, and natural gas; manufactures and sells chemical products used in oil and gas field exploration, oil and gas distribution, oil field drilling, wastewater processing, papermaking chemical agents and inorganic chemicals, and manufactures and sells materials for human and animal antibiotics. It operates in four segments: Bromine, Crude Salt, Chemical Products and Natural Gas. It derives maximum revenue from the Bromine segment which is commonly used in brominated flame retardants, fumigants, water purification compounds, dyes, medicines and disinfectants.

Share on Social Networks: